Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood has made a name for herself as an innovation-focused growth investor, and her leadership as the founder and CEO of Ark Invest has led some investors to pay close attention to the equity purchases and sales in the various exchange-traded funds (ETFs) managed by the company. While performance across her funds has been mixed in recent years, Wood's top picks have tended to post explosive gains across the stretch.

With that in mind, read on for a look at the three most recent stocks purchased for the company's flagship Ark Innovation ETF (NYSEMKT: ARKK).

Image source: Getty Images.

1. Figma

As of this writing, Figma (NYSE: FIG) is the most recent stock to be purchased for Cathie Wood's Ark Innovation ETF. Ark purchased shares of the stock for the fund on Feb. 23, marking the third time it had purchased shares of the design-collaboration software specialist in the month.

Figma only ranks as the Ark Innovation ETF's 38th-largest holding as of the most recent update, accounting for approximately 0.66% of the total portfolio. On the other hand, Figma has the distinction of being one of just a handful of stocks that the fund increased exposure to in the second half of February.

Figma has seen volatile trading over the last six months as investors weigh concerns about decelerating growth and long-term profitability. On the other hand, sales still grew 40% year over year in the fourth quarter -- and the business posted an adjusted operating margin of 14% in the period. While Figma is a high-risk, high-reward play, Wood and Ark are clearly bullish on the company's outlook.

2. CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ: CRSP) has long been one of the biggest holdings in the Ark Innovation ETF, and Wood's flagship fund once again purchased more shares of the gene-editing specialist's stock on Feb. 20. As of this writing, CRISPR stands as the second-largest holding in the fund and accounted for 6.64% of total portfolio weight.

CRISPR is a biotech company that's generating relatively little revenue, posting sales of just $3.5 million last year. On the other hand, the company could wind up delivering explosive growth if even a small number of the gene-editing drug candidates in its pipeline see meaningful commercialization. For better or worse, CRISPR is a speculative growth play that could play a big role in shaping the Ark Innovation ETF's performance over the next five years.

3. CoreWeave

CoreWeave (NASDAQ: CRWV) is a provider of data center services and has benefited from surging demand connected to the rise of artificial intelligence (AI) processing. Ark purchased more of the company's shares for its Innovation ETF on Feb. 20, and CoreWeave now stands as the 18th-largest holding in the ETF. The AI stock accounts for roughly 2% of the fund's total holdings.

CoreWeave has already been posting strong sales growth in conjunction with sky-high AI processing needs, and it has some big new catalysts on deck for 2026. The company secured access to large orders of Nvidia's next-generation Rubin graphics processing units (GPUs) and Vera central processing units (CPUs), which could allow it to attract large service demand in a hardware-constrained environment.

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics, Figma, and Nvidia. The Motley Fool has a disclosure policy.